Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772457 | 1.00 | — | — | |
| SCHEMBL40810 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL3077600 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL3079047 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL360309 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL2897919 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL3078484 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL3078185 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL3031889 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL3064137 | 1.00 | ALDH1A1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185336-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2023-05-31 | — | — | EP | claimed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | claimed |
| US-20040122250-A1 | Mesoporous organic-inorganic hybrid materials for separating gases | CENTRE NATIONAL DE LA RECHERCHE-SCIENTIFIQUE (FR) | 2004-06-24 | — | — | US | claimed |
| EP-4291252-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022171869-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-08-18 | — | — | WO | disclosed |
| US-9035023-B2 | Bombesin analog peptide antagonist conjugates | Piramal Imaging, SA (CH) | 2015-05-19 | — | — | US | disclosed |
| US-7833331-B2 | Non-toxic corrosion-protection pigments based on cobalt | UNIVERSITY OF DAYTON (US) | 2010-11-16 | — | — | US | disclosed |
| US-7789958-B2 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1017275-B1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | MURPHY MICHAEL A (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090163628-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON COBALT | STURGILL JEFFREY ALLEN | 2009-06-25 | — | — | US | disclosed |
| US-7517512-B2 | Mesoporous organic-inorganic hybrid materials for separating gases | CENTRE NATIONAL DE LA RECHERCHE-SCIENTIFIQUE (FR) | 2009-04-14 | — | — | US | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-6576672-B1 | Parkingson's Disease and dementias characterized by mito-chondrial damage; such as 3,7-diazanonane-1,9-diamine; neutralizing dopamine depriving effect | MURPHY MICHAEL A (US) | 2003-06-10 | — | — | US | disclosed |
| EP-1017275-A4 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | MURPHY MICHAEL A (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2000071542-A1 | IMPROVED SYNTHESIS OF A TETRAAMIDO MACROCYCLE LIGAND | THE CLOROX COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1017275-A1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | Murphy, Michael A. (US) | 2000-07-12 | — | — | EP | disclosed |
| US-5906996-A | Tetramine treatment of neurological disorders | MURPHY MICHAEL A (US) | 1999-05-25 | — | — | US | disclosed |
| WO-1999008519-A1 | POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS | MURPHY MICHAEL A (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1996011189-A1 | POLYAZACYCLOALKANE DERIVATIVES, THEIR METAL COMPLEXES AND PHARMACEUTICAL PRODUCTS INCORPORATING THESE COMPLEXES | L'AIR LIQUIDE SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122250-A1 | Mesoporous organic-inorganic hybrid materials for separating gases | SCO2, IPO9, IPO4 | ALDH1A1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.